https://www.selleckchem.com/pr....oducts/cerdulatinib-
nce return to work may be beneficial for patients undergoing SCS. HD-SCS may lead to significantly increased HRQOL at 12 months in patients with FBSS. Despite the increase, reaching the HRQOL level of matched controls was not achieved. Only a limited number of patients were able to return to work. This finding indicates that specialized programs to enhance return to work may be beneficial for patients undergoing SCS.In two experiments, the authors investigated the influence of stress type (i.e., low/no stress, men
Like
Comment
Share